Alto NeuroscienceANRO +1.57%12 Quick Ratio is 20.52 as of Mar. 2026, which is 31% above its 10-year median of 15.69. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Alto Neuroscience ranks better than 92.87% on this metric.
Alto Neuroscience has a quick ratio of 20.52. It generally indicates good short-term financial strength.
The historical rank and industry rank for Alto Neuroscience's Quick Ratio or its related term are showing as below:
ANRO'
s Quick Ratio Range Over the Past 10 Years
Min: 8.7 Med: 15.69 Max: 26.02
Current: 20.52
During the past 5 years, Alto Neuroscience's highest Quick Ratio was 26.02. The lowest was 8.70. And the median was 15.69.
ANRO's Quick Ratio is ranked better than 92.87% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs ANRO: 20.52
Alto Neuroscience (NYSE:ANRO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Alto Neuroscience Quick Ratio Related Terms
Alto Neuroscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Alto Neuroscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alto Neuroscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Alto Neuroscience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alto Neuroscience (ANRO) has a Quick Ratio of 20.52 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alto Neuroscience and its competitors. This is 31% above median its historical median of 15.69. Over the past decade, Alto Neuroscience's Quick Ratio has ranged from 8.70 to 26.02. According to the industry distribution chart, Alto Neuroscience ranks #101 out of 1417 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Alto Neuroscience's Quick Ratio too high?
Alto Neuroscience's current Quick Ratio of 20.52 is 31% above median its 10-year median of 15.69. Over the past 10 years, this metric has ranged from a low of 8.70 to a high of 26.02. The Biotechnology industry median Quick Ratio is 3.60. Alto Neuroscience's value of 20.52 is 470% above this industry median. Based on the distribution chart, Alto Neuroscience ranks #101 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Quick Ratio compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #101 out of 1417 companies for Quick Ratio. This places Alto Neuroscience in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Alto Neuroscience's value of 20.52 is 470% above this benchmark. Historically, Alto Neuroscience's own Quick Ratio has ranged from 8.70 to 26.02 over the past decade. While the company's 10-year median is 15.69 vs. the industry median of 3.60, Alto Neuroscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current Quick Ratio of 20.52 is 470% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alto Neuroscience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current Quick Ratio is 20.52, which is 31% above median its own 10-year median of 15.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Quick Ratio of 20.52. The current Quick Ratio is 20.52, which is 31% above median its 10-year median of 15.69 and 470% above the Biotechnology industry median of 3.60. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Quick Ratio is 20.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
